2Marang -van de Mheen PJ, van Maarle MC, Stouthard ME. Getting insurance after genetic screening on familial hypercholesterelaemia; the need to educate both insurers and the public to increase adherence to naXional guidelines in the Netherlands [ J ]. J Epidemiol Community Health, 2002, 56 (2): 145-147.
3Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial h'ypercholesterelaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atheroscleresis Society [ J]. Eur Hear J, 2013, 34 (45) : 3478 -3490a.
4Ose I Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children [ J ]. Semin Vasc Med, 2004, 4 (1): 51-57.
5Brown MS, Ho YK, Goldstein JL. The low -density lipoprotein pathway in human fibroblasts: relation between cell surface receptor binding and endocytosis of low - density lipoprotein [ J ]. Ann N Y Acad Sci, 1976, 275: 244-257.
6Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia [ J ]. J Clin Invest, 1986, 78 (5): 1410-1414.
7Broekhuizen K, Jelsma JG, van Poppel MN, et al. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviors in people with familial hypercholesterolemia? [ J ]. BMC Public Health, 2012, 12: 348.
8Smith SC Jr, Allen J, Blair SN, et al. AI-IA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute [ J . Circulation, 2006, 113 (19): 2363-2372.
9Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects : a systematic review with meta - analysis [J]. J Am Call Nutr, 2006, 25 (1): 41 - 48.
